NASDAQ$SHC
Sotera Health Company · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Sotera Health's Q2 2024 performance saw revenue growth, but net income decreased due to debt refinancing charges.
Sotera Health reported an 8% increase in net revenues to $277 million for Q2 2024. However, net income decreased to $9 million, or $0.03 per diluted share, primarily due to charges associated with debt refinancing. Adjusted EBITDA increased by 7% to $137 million, while Adjusted EPS declined slightly to $0.19.
- Net revenues for Q2 2024 increased by 8% to $277 million compared to Q2 2023.
- Net income for Q2 2024 was $9 million, or $0.03 per diluted share, down from $24 million, or $0.08 per diluted share in Q2 2023.
- Adjusted EBITDA for Q2 2024 increased by 7% to $137 million compared to Q2 2023.
- The company successfully refinanced its debt structure, extending debt maturities to 2031 and reaffirmed its 2024 outlook.
Headline financials
Revenue & EPS history
Sotera Health · Revenue · Quarterly
$277M
Revenue by segment
Sotera Health · $263M total across 3 segments · Q3 2023
- Sterigenics$168M+6.7%64.0%
- Nelson Labs$54.7M-2.1%20.8%
- Nordion$40.1M+14.3%15.2%
Forward guidance
Sotera Health reaffirmed its 2024 outlook.
Tailwinds
- Net revenues and Adjusted EBITDA growth in the range of 4.0% to 6.0%.
- Interest Expense in the range of $165 million to $175 million.
- Tax rate applicable to Adjusted Net Income in the range of 31.5% to 34.5%.
- Adjusted EPS in the range of $0.67 to $0.75.
- Capital expenditures in the range of $205 million to $225 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-2.7%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.4%
Avg return
30 days after
25%
6 / 24 earnings
Positive
+11.2%
Q2 2024
Best reaction
-15.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | +2.6% | +1.2% | |
| Q4 2025 | -0.5% | -7.1% | -22.6% | |
| Q3 2025 | -1.1% | -5.6% | -0.3% | |
| Q1 2025 | +5.2% | +11.7% | +6.4% | |
| Q4 2024 | -10.0% | -15.9% | -13.7% | |
| Q3 2024 | +2.0% | +1.8% | -17.9% | |
| Q2 2024 | +11.2% | +10.1% | +16.6% | |
| Q1 2024 | -2.2% | +1.8% | -0.8% | |
| Q4 2023 | -12.3% | -14.7% | -29.6% | |
| Q3 2023 | +1.2% | +5.8% | +10.6% | |
| Q2 2023 | -3.7% | -7.1% | -13.4% | |
| Q1 2023 | -7.5% | -7.9% | -9.2% | |
| Q4 2022 | -0.5% | +3.9% | +2.0% | |
| Q3 2022 | -10.6% | -7.7% | +28.6% | |
| Q2 2022 | +2.1% | +4.2% | -6.7% | |
| Q1 2022 | -2.8% | -5.4% | +3.7% | |
| Q4 2021 | -8.4% | -11.4% | -1.0% | |
| Q4 2019 | -8.4% | -11.4% | -1.0% | |
| Q3 2021 | -15.9% | -13.7% | -20.0% | |
| Q2 2021 | -0.7% | -6.3% | +1.0% | |
| Q2 2020 | -0.7% | -6.3% | +1.0% | |
| Q1 2021 | -5.4% | -3.4% | +3.5% | |
| Q1 2020 | -5.4% | -3.4% | +3.5% | |
| Q4 2020 | +8.9% | +13.6% | +1.4% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro